These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Venlafaxine extended-release: a review of its use in the management of major depression. Wellington K; Perry CM CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036 [TBL] [Abstract][Full Text] [Related]
4. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Shelton C; Entsuah R; Padmanabhan SK; Vinall PE Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485 [TBL] [Abstract][Full Text] [Related]
5. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Kim TS; Pae CU; Yoon SJ; Bahk WM; Jun TY; Rhee WI; Chae JH Psychiatry Clin Neurosci; 2006 Jun; 60(3):347-51. PubMed ID: 16732752 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. Feighner JP; Entsuah AR; McPherson MK J Affect Disord; 1998 Jan; 47(1-3):55-62. PubMed ID: 9476744 [TBL] [Abstract][Full Text] [Related]
7. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA; J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433 [TBL] [Abstract][Full Text] [Related]
8. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870 [TBL] [Abstract][Full Text] [Related]
9. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Owens MJ; Krulewicz S; Simon JS; Sheehan DV; Thase ME; Carpenter DJ; Plott SJ; Nemeroff CB Neuropsychopharmacology; 2008 Dec; 33(13):3201-12. PubMed ID: 18418363 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Kennedy SH; Andersen HF; Lam RW J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428 [TBL] [Abstract][Full Text] [Related]
11. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Einarson TR; Arikian SR; Casciano J; Doyle JJ Clin Ther; 1999 Feb; 21(2):296-308. PubMed ID: 10211533 [TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Davidson JR; DuPont RL; Hedges D; Haskins JT J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635 [TBL] [Abstract][Full Text] [Related]
13. Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder. Fagiolini A; Cardoner N; Pirildar S; Ittsakul P; Ng B; Duailibi K; El Hindy N Expert Opin Pharmacother; 2023; 24(15):1715-1723. PubMed ID: 37501324 [TBL] [Abstract][Full Text] [Related]
14. Effects of paroxetine and venlafaxine XR on heart rate variability in depression. Davidson J; Watkins L; Owens M; Krulewicz S; Connor K; Carpenter D; Krishnan R; Nemeroff C J Clin Psychopharmacol; 2005 Oct; 25(5):480-4. PubMed ID: 16160626 [TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W; Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199 [TBL] [Abstract][Full Text] [Related]
16. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. Silverstone PH; Ravindran A J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Kaplan EM Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302 [TBL] [Abstract][Full Text] [Related]
19. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. Sir A; D'Souza RF; Uguz S; George T; Vahip S; Hopwood M; Martin AJ; Lam W; Burt T J Clin Psychiatry; 2005 Oct; 66(10):1312-20. PubMed ID: 16259546 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Silverstone PH; Salinas E J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]